No abstract

dose (BED) is high in the target volume, with low dose outside the target volume and small side effect. The overall survival rates of 1-, 2-, 3-year to patients with stage I -II NSCLC were 88%, 78% and 78%. One case of grade III radiation pneumonitis was observed. The overall survival rates of 1-, 2-, 3-, 4-, 5-year to patients with stage I -II liver cancer were 83%, 75%, 58%, 42% and 34% respectively. No liver function damaged was observed during treatment. The grade I -II liver damage was 14%, and 4% with grade III. The overall survival rates of 1-, 2-, 3-, 4-, 5-year to patients with stage I and II pancreatic cancer were 68%, 34%, 30%, 21%, and 17% respectively. The grade I and II gastrointestinal late reaction rate was 9%, and 3% with grade III. Conclusions: The highly focused, hypofractional g-ray SBRT resulted in promising local control and survival rate with minimal toxicity in the treatment of solid organ malignancies, including lung cancer, hepatocarcinoma and pancreatic carcinoma. As a safe and effective radiotherapy technique, it is worthy of being studied and applicated.

No abstract

No abstract